Potassium Chloride

Pharmacologic Category

Electrolyte Supplement, Oral; Electrolyte Supplement, Parenteral

Dosing: Adult

Note: When maintaining normal daily requirements, IV doses should be incorporated into the patient's maintenance IV fluids. Intermittent IV potassium administration should be reserved for more severe depletion situations in patients undergoing ECG monitoring. Doses expressed as mEq of potassium.

Normal daily requirements: Oral, IV: 40 to 80 mEq/day

Prevention of hypokalemia: Oral: 20 to 40 mEq/day in 1 to 2 divided doses

Treatment of hypokalemia:

Oral:

Mild to moderate hypokalemia: Note: If deficits are severe or ongoing losses are great, IV route should be considered.

Capsules, tablets, oral solution: Usual dose: 40 to 100 mEq daily in divided doses; limit single doses to 20 to 25 mEq/dose to avoid GI discomfort.

Powder for oral solution (Klor-Con): Usual dose: 40 to 100 mEq daily in 2 to 5 divided doses; limit single doses to 40 mEq/dose; maximum: 200 mEq/24 hours.

Note: Some clinicians initiate treatment with 10 to 20 mEq given 2 to 4 times per day (20 to 80 mEq/day), depending upon the severity of the hypokalemia. Total daily doses up to 120 mEq may be necessary as determined by laboratory assessment, patient symptoms and/or ongoing losses (Brophy 2014).

Severe hypokalemia: Some clinicians initiate treatment with 40 mEq given 3 to 4 times per day; may also administer 20 mEq every 2 to 3 hours in conjunction with IV potassium administration with careful monitoring. Administration of dose >40 mEq orally per dose are typically not well tolerated, resulting in GI irritation and nausea.

IV intermittent infusion: Peripheral or central line: ≤10 mEq/hour; repeat as needed based on frequently obtained lab values; central line infusion and continuous ECG monitoring highly recommended for infusions >10 mEq/hour.

Potassium dosage/rate of infusion general guidelines (per product labeling): Note: High variability exists in dosing/infusion rate recommendations; therapy guided by patient condition and specific institutional guidelines. As an estimate, 10 mEq of potassium chloride will roughly increase serum levels by 0.1 mEq/L. Patients with more severe forms of hypokalemia (eg, serum potassium levels <3.5 mEq/L) may require increased amounts due to total body potassium deficit (Flurie 2017).

Serum potassium >2.5 to 3.5 mEq/L: Maximum infusion rate: 10 mEq/hour; maximum concentration: 40 mEq/L; maximum 24-hour dose: 200 mEq

Serum potassium <2.5 mEq/L or symptomatic hypokalemia (excluding emergency treatment of cardiac arrest): Maximum infusion rate (central line only): 40 mEq/hour in presence of continuous ECG monitoring and frequent lab monitoring; in selected situations, patients may require up to 400 mEq/24 hours.

Dosing: Geriatric

Refer to adult dosing. Use with caution, starting at the low end of the dosage range.

Dosing: Renal Impairment: Adult

There are no specific dosage adjustments provided in the manufacturer's labeling. Reduce initial dose by at least 50% in patients with renal impairment (Kraft 2005). Contraindicated in patients with renal failure.

Dosing: Hepatic Impairment: Adult

There are no specific dosage adjustments provided in the manufacturer's labeling; use oral formulations with caution in patients with cirrhosis and start at the low end of dosage range.

Dosing: Pediatric

Note: Maintenance potassium IV doses should be incorporated into the patient's maintenance IV fluids; intermittent IV potassium administration should be reserved for severe depletion situations; continuous ECG monitoring should be used for intermittent IV doses >0.5 mEq/kg/hour. Oral solutions are available in two concentrations: 20 mEq/15 mL (1.33 mEq/mL) and 40 mEq/15 mL (2.67 mEq/mL); use extra precaution; verify product formulation for dosage calculation.

Hypokalemia, prevention for ongoing drug losses (eg, concurrent diuretic therapy): Limited data available: Infants, Children, and Adolescents: Oral: 1 to 2 mEq/kg/day in 1 to 2 divided doses; usual single dose should not exceed usual adult single dose: 20 mEq/dose; although some patients may require a single dose up to 40 mEq/dose (Moffett 2011); some patients may require higher individual daily doses based on lab values and ongoing losses.

Hypokalemia, treatment; mild to moderate: Limited data available: Infants, Children, and Adolescents: Oral: 2 to 5 mEq/kg/day in divided doses; not to exceed 1 to 2 mEq/kg as a single dose or 20 mEq (whichever is less) (ASPEN [Corkins 2015]; Moffett 2011); if deficits are severe or ongoing losses are great, IV potassium route should be considered as preferred route of administration.

Hypokalemia, treatment; severe: Infants, Children, and Adolescents: Intermittent IV infusion: 0.5 to 1 mEq/kg/dose; maximum dose: 40 mEq/dose; infuse at a rate ≤0.5 mEq/kg/hour (see Administration for more detail on rate) (ASPEN [Corkins 2015]; Fuhrman 2017; Kliegman 2016); serum concentrations should be evaluated 1 to 2 hours after completion of infusion; may repeat as needed based on lab values; severe depletion or ongoing losses may require >200% of normal daily maintenance (Knudson 2013).

Parenteral nutrition, maintenance potassium requirement (ASPEN [Mirtallo 2004]):

Infants and Children weighing ≤50 kg: IV: 2 to 4 mEq/kg/day of potassium as an additive to parenteral nutrition solution.

Children weighing >50 kg and Adolescents: IV: 1 to 2 mEq/kg/day of potassium as an additive to parenteral nutrition solution.

Dosing: Renal Impairment: Pediatric

There are no specific dosage adjustments provided in the manufacturer's labeling. Reduce initial dose by at least 50% in adult patients with renal impairment (Kraft 2005). Contraindicated in patients with renal failure.

Dosing: Hepatic Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling.

Use: Labeled Indications

Hypokalemia: Treatment or prevention of hypokalemia.

Administration: IV

Potassium must be diluted prior to parenteral administration. For IV infusion; do not administer IV push. In general, the rate of administration may be dependent on patient condition and specific institution policy.

Some clinicians recommend that the maximum concentration for peripheral infusion is 10 mEq/100 mL and maximum rate of administration for peripheral infusion is 10 mEq/hour (Kraft 2005). ECG monitoring is recommended for peripheral or central infusions >10 mEq/hour in adults (Kraft 2005). With central line administration, higher concentrations and more rapid rates of infusion may be used; concentrations of 20 to 40 mEq/100 mL at a maximum rate of 40 mEq/hour via central line have been safely administered (Hamill 1991; Kruse 1990).

Vesicant/irritant (at concentrations >0.1 mEq/mL); ensure proper needle or catheter placement prior to and during IV infusion. Avoid extravasation.

Extravasation management: If extravasation occurs, stop infusion immediately and disconnect (leave needle/cannula in place); gently aspirate extravasated solution (do NOT flush the line); initiate hyaluronidase antidote; remove needle/cannula; apply dry cold compresses (Hurst 2004; Reynolds 2014); elevate extremity.

Hyaluronidase: Intradermal or SubQ: Inject a total of 1 to 1.7 mL (15 units/mL) as five separate 0.2 to 0.3 mL injections (using a 25-gauge needle) into area of extravasation at the leading edge in a clockwise manner (MacCara 1983; Reynolds 2014; Zenk 1981).

Administration: Oral

Oral dosage forms should be taken with meals and a full glass of water or other liquid to minimize the risk of GI irritation. Prescribing information for the various oral preparations recommend that no more than 20 mEq or 40 mEq should be given as single dose.

Capsule: MicroK: Swallow whole, do not chew. Capsules may also be opened and contents sprinkled on a spoonful of applesauce or pudding and should be swallowed immediately without chewing.

Powder for oral solution: Klor-Con: Dissolve one packet in at least 120 mL of cold water or other beverage prior to administration. If GI irritation occurs, increase dilution.

Tablet:

K-Tab, Kaon-Cl, Klor-Con: Swallow tablets whole; do not crush, chew, or suck on tablet.

Klor-Con M: Swallow tablets whole; do not crush, chew, or suck on tablet. Tablet may also be broken in half and each half swallowed separately; the whole tablet may be dissolved in ~4 ounces of water (allow ~2 minutes to dissolve, stir well and drink immediately)

Administration: Pediatric

Oral: Note: Should be taken with meals and a full glass of water or other liquid to minimize the risk of GI irritation. Prescribing information for the various oral preparations recommend that no more than 20 mEq or 25 mEq should be given as single dose.

Capsule: MicroK: Swallow whole, do not chew; may also be opened and contents sprinkled on a spoonful of applesauce or pudding and swallowed immediately without chewing

Oral solution: Available in two concentrations: 20 mEq/15 mL (1.33 mEq/mL) and 40 mEq/15 mL (2.67 mEq/mL); verify product formulation for dosage calculations. Do not administer full strength; must be diluted prior to administration.

Powder (Klor-Con): Dissolve in water or juice

Tablets, Sustained release and wax matrix:

K-Tab, Kaon-Cl-10, Klor-Con: Swallow whole, do not crush or chew; administer with food

Klor-Con M: Tablet may be broken in half and each half swallowed separately; the whole tablet may also be dissolved in water

Parenteral: Potassium must be diluted prior to parenteral administration. Do not administer IV push. In general, the dose, concentration of infusion and rate of administration may be dependent on patient condition and specific institution policy.

Infusion rates (including all sources) (Fuhrman 2017; Hamill 1991; Klaus 1989; Kliegman 2016; Kruse 1990; Lafraniere 2006; Schaber 1985):

Noncritical care settings: Usual range: 0.2 to 0.5 mEq/kg/hour up to 10 mEq to 20 mEq/hour have been used.

Critical care settings/situations: Higher rates may be used; maximum rate: 1 mEq/kg/hour up to 40 mEq/hour; continuous cardiac monitoring recommended for rates >0.5 mEq/kg/hour

Vesicant/irritant (at concentrations >0.1 mEq/mL); ensure proper needle or catheter placement prior to and during IV infusion. Avoid extravasation. If extravasation occurs, stop infusion immediately and disconnect (leave needle/cannula in place); gently aspirate extravasated solution (do NOT flush the line); initiate hyaluronidase antidote (see Management of Drug Extravasations for more details); remove needle/cannula; apply dry cold compresses (Hurst 2004; Reynolds 2014); elevate extremity.

Vesicant/Extravasation Risk

Vesicant/irritant (at concentrations >0.1 mEq/mL)

Dietary Considerations

Administer with plenty of fluid to decrease stomach irritation and discomfort. Some dietary sources of potassium include leafy green vegetables (eg, spinach, cabbage), tomatoes, cucumbers, zucchini, fruits (eg, apples, oranges, and bananas), root vegetables (eg, carrots, radishes), beans, and peas.

Storage/Stability

Capsule, tablet: Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Protect from light and moisture.

Powder for oral solution: Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F). Protect from light.

Solution for injection: Store at 25°C (77°F); do not freeze; avoid excessive heat. Use only clear solutions. Potassium chloride is compatible when admixed in most common infusion solutions. Refer to institution-specific policies and procedures for stability information.

Preparation for Administration: Adult

Parenteral: Potassium must be diluted prior to parenteral administration. The concentration of infusion may be dependent on patient condition and specific institution policy. Some clinicians recommend that the maximum concentration for peripheral infusion is 10 mEq/100 mL and 20-40 mEq/100 mL for central infusions.

Preparation for Administration: Pediatric

Oral:

Oral solution: Available in two concentrations: 20 mEq/15 mL (1.33 mEq/mL) and 40 mEq/15 mL (2.67 mEq/mL); verify product formulation for dosage calculations. To avoid gastrointestinal irritation, the manufacturer recommends diluting 15 mL of KCl oral solution (either strength) in at least 6 ounces of water or juice. In postcardiac surgery pediatric patients (including neonates and infants), oral KCl solution was administered at a concentration of 2.67 mEq/mL followed by an equivalent volume of sterile water as a flush (Moffett 2011).

Powder:

Klor-Con: Dissolve one 20 mEq packet in 4 ounces of water or other beverage

Klor-Con/25: Dissolve one 25 mEq packet in 5 ounces of water or other beverage

Tablet (Klor-Con M): May dissolve whole tablet in approximately 4 ounces of water; allow approximately 2 minutes to dissolve, stir well, and drink immediately.

Parenteral: Potassium must be diluted prior to parenteral administration. The concentration of infusion may be dependent on patient condition and specific institution policy. The maximum concentrations should be reserved for specific clinical situations (eg, fluid-restricted).

Specific pediatric data limited and based on recommendations in adult patients and reported clinical experience for some pediatric centers (Corkins 2015; Hamill 1991; Klaus 1989; Kraft 2005; Kruse 1990; Lafraniere 2006; Murray 2014; Schaber 1985).

For peripheral administration, further dilution to a concentration ≤80 mEq/L (0.08 mEq/mL) for continuous infusion has been used; usual reported concentration is 40 to 60 mEq/L (0.04 to 0.06 mEq/mL).

For central line infusion, a maximum concentration up to 200 mEq/L (0.2 mEq/mL) has been used for infusions; usual reported concentration is 120 to 150 mEq/L (0.12 to 0.15 mEq/mL); for potassium replacement (intermittent), higher concentration of 400 mEq/L (0.4 mEq/mL) has been used.

Compatibility

See Trissel’s IV Compatibility Database

Open Trissel's IV Compatibility

Medication Patient Education with HCAHPS Considerations

What is this drug used for?

• It is used to treat or prevent low potassium levels.

Frequently reported side effects of this drug

• Abdominal pain

• Nausea

• Vomiting

• Diarrhea

• Passing gas

• Tablet wax in stool

Other side effects of this drug: Talk with your doctor right away if you have any of these signs of:

• High potassium like abnormal heartbeat, confusion, dizziness, passing out, weakness, shortness of breath, or numbness or tingling feeling

• Slow heartbeat

• Chest pain

• Low sodium like headache, difficulty focusing, trouble with memory, confusion, weakness, seizures, or change in balance

• Bowel problems like black, tarry, or bloody stools; fever; mucus in stools; vomiting; vomiting blood; severe abdominal pain; constipation; or diarrhea

• Abdominal swelling

• Shortness of breath

• Excessive weight gain

• Swelling of arms or legs

• Severe injection site pain, edema, or irritation

• Signs of a significant reaction like wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat.

Note: This is not a comprehensive list of all side effects. Talk to your doctor if you have questions.

Consumer Information Use and Disclaimer: This information should not be used to decide whether or not to take this medicine or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a brief summary of general information about this medicine. It does NOT include all information about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this medicine. This information is not specific medical advice and does not replace information you receive from the healthcare provider. You must talk with the healthcare provider for complete information about the risks and benefits of using this medicine.

Medication Safety Issues

Sound-alike/look-alike issues:

High alert medication:

Other safety concerns:

Contraindications

Hypersensitivity to potassium chloride or any component of the formulation; hyperkalemia, renal failure, and conditions in which potassium retention is present; structural, pathological, and/or pharmacologic cause for delay or arrest in passage through the GI tract (solid oral dosage forms only).

Canadian labeling: Additional contraindications (not in US labeling): Injection: Renal impairment with oliguria, anuria, or azotemia; Addison disease (untreated); ventricular fibrillation; salt-losing adrenal hyperplasia; extensive tissue breakdown as in severe burns, acute dehydration, and heat cramps; increased sensitivity to potassium administration (eg, congenital paramyotonia, adynamia episodica hereditaria); hyperadrenalism associated with adrenogenital syndrome; digitalis-induced, second- or third-degree heart block.

Warnings/Precautions

Concerns related to adverse effects:

• Extravasation: Vesicant/irritant (at concentrations >0.1 mEq/mL); ensure proper catheter or needle position prior to and during infusion. Avoid extravasation.

• Hyperkalemia: May occur with IV or oral use. Potentially fatal hyperkalemia can develop rapidly and be asymptomatic. Use with caution or avoid use in patients with predisposing conditions for hyperkalemia (eg, chronic or severe renal impairment, extensive burns or tissue injury, heart failure, acute dehydration, systemic acidosis, adrenal insufficiency, or the administration of potassium-sparing diuretics). Monitor serum potassium closely.

• Hypersensitivity/infusion reactions: Hypersensitivity/infusion reactions, including anaphylaxis and chills, may occur with parenteral administration of potassium containing solutions. Discontinue immediately if signs/symptoms of hypersensitivity/infusion reactions develop.

• Hyponatremia: Parenteral administration may cause hyponatremia; risk may be increased in children, elderly patients, postoperatively, in patients with psychogenic polydipsia, and with concurrent use of medications that may decrease sodium (eg, diuretics). Monitor serum sodium as clinically indicated.

Disease-related concerns:

• Acid/base disorders: Use with caution in patients with acid/base alterations or acid/base correction; hyperosmolality or acidosis (or correction of alkalosis) is associated with hyperkalemia (shift of intracellular potassium to extracellular space); monitor serum potassium closely.

• Cardiovascular disease: Use with caution in patients with cardiovascular disease (eg, heart failure, cardiac arrhythmias, atrioventricular [AV] block); patients may be more susceptible to life-threatening cardiac effects associated with hyper/hypokalemia.

• Hepatic impairment: Use with caution in patients with cirrhosis; monitor serum potassium more frequently.

• Renal impairment: Use with caution in patients with renal impairment; monitor serum potassium closely. Contraindicated in patients with renal failure.

Concurrent drug therapy issues:

• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.

Dosage form specific issues:

• Oral formulations: May cause GI upset and irritation (eg, nausea, vomiting, diarrhea, abdominal pain, discomfort) and lead to GI ulceration, bleeding, perforation, and/or obstruction. Oral liquid preparations (not solid) should be used in patients with esophageal compression or delayed gastric emptying. Extended-release formulations of potassium chloride may result in a “ghost tablet” in the stool.

Other warnings/precautions:

• Parenteral administration: Use extreme caution with parenteral administration and monitor serum potassium concentrations closely. Evaluate renal function, cardiac and fluid status, and any factors contributing to altered potassium concentrations (eg, acidosis, alkalosis) prior to therapy. Do NOT administer undiluted or IV push; inappropriate parenteral administration may be fatal. Always administer potassium further diluted; refer to appropriate dilution and administration rate recommendations. Pain and phlebitis may occur during parenteral infusion requiring a decrease in infusion rate or potassium concentration.

Geriatric Considerations

Elderly may require less potassium than younger adults due to decreased renal function. For the elderly who do not respond to replacement therapy, check serum magnesium. Long-term use of diuretics and proton-pump inhibitors may result in hypomagnesemia. Concomitant use of a loop diuretic and potassium chloride supplement is common. Attention should be paid to discontinuation of potassium supplementation should the loop diuretic be discontinued.

Pregnancy Considerations

Potassium requirements are the same in pregnant and nonpregnant women. Adverse events have not been observed following use of potassium supplements in healthy women with normal pregnancies. Use caution in pregnant women with other medical conditions (eg, preeclampsia; may be more likely to develop hyperkalemia) (IOM 2004). Potassium supplementation (that does not cause maternal hyperkalemia) would not be expected to cause adverse fetal events.

Breast-Feeding Considerations

Potassium is present in breast milk (IOM 2004). The normal content of potassium in human milk is ~13 mEq/L. Supplementation (that does not cause maternal hyperkalemia) would not be expected to affect normal concentrations.

Briggs' Drugs in Pregnancy & Lactation

• Potassium Chloride

Adverse Reactions

Frequency not defined:

Cardiovascular: Cardiac arrhythmia, cardiac conduction disturbance, edema, peripheral edema

Endocrine & metabolic: Fluid and electrolyte disturbance, hypervolemia

Gastrointestinal: Abdominal cramps, abdominal distress, abdominal pain, diarrhea, flatulence, gastrointestinal hemorrhage, gastrointestinal irritation, gastrointestinal obstruction, gastrointestinal perforation, gastrointestinal ulcer, nausea, vomiting

Respiratory: Pulmonary edema

Postmarketing: Angioedema, asystole (with rapid administration or hyperkalemia), bradycardia, burning sensation at injection site, chest pain, dyspnea, encephalopathy (hyponatremic), erythema at injection site, hyperkalemia, hypersensitivity reaction, hyponatremia, infusion-site pain, injection site phlebitis, irritation at injection site, skin rash, swelling at injection site, venous thrombosis at injection site, ventricular fibrillation (with rapid administration or hyperkalemia)

Metabolism/Transport Effects

None known.

Drug Interactions Open Interactions

Aliskiren: Potassium Salts may enhance the hyperkalemic effect of Aliskiren. Risk C: Monitor therapy

Angiotensin II Receptor Blockers: Potassium Salts may enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. Risk C: Monitor therapy

Angiotensin-Converting Enzyme Inhibitors: Potassium Salts may enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors. Risk C: Monitor therapy

Anticholinergic Agents: May enhance the ulcerogenic effect of Potassium Chloride. Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride. Risk X: Avoid combination

Drospirenone: Potassium Salts may enhance the hyperkalemic effect of Drospirenone. Risk C: Monitor therapy

Eplerenone: May enhance the hyperkalemic effect of Potassium Salts. Management: This combination is contraindicated in patients receiving eplerenone for treatment of hypertension. Risk D: Consider therapy modification

Glycopyrrolate (Systemic): May enhance the adverse/toxic effect of Potassium Chloride. This is specific to solid oral dosage forms of potassium chloride. Risk X: Avoid combination

Heparin: May enhance the hyperkalemic effect of Potassium Salts. Risk C: Monitor therapy

Heparins (Low Molecular Weight): May enhance the hyperkalemic effect of Potassium Salts. Risk C: Monitor therapy

Nicorandil: May enhance the hyperkalemic effect of Potassium Salts. Risk C: Monitor therapy

Potassium-Sparing Diuretics: Potassium Salts may enhance the hyperkalemic effect of Potassium-Sparing Diuretics. Risk D: Consider therapy modification

Monitoring Parameters

Electrolytes (including serum potassium, calcium, chloride, magnesium, phosphate, sodium), acid/base balance; renal function; cardiac monitor (if intermittent infusion or potassium infusion rates 0.5 mEq/kg/hour in children or >10 mEq/hour in adults); to assess adequate replacement, repeat serum potassium level 2 to 4 hours after dose; monitor potassium levels daily for treatment and monthly to biannually for prophylaxis. Monitor IV infusion site.

Reference Range

Note: Reference ranges may vary depending on the laboratory

Serum potassium: 3.5 to 5.2 mEq/L

Nursing Physical Assessment/Monitoring

Monitor infusion site closely.

Dosage Forms Considerations

750 mg potassium chloride = elemental potassium 390 mg = potassium 10 mEq = potassium 10 mmol

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Capsule Extended Release, Oral:

Klor-Con Sprinkle: 8 mEq [contains brilliant blue fcf (fd&c blue #1)]

Klor-Con Sprinkle: 10 mEq [contains fd&c red #40, fd&c yellow #10 (quinoline yellow)]

Micro-K: 8 mEq [DSC], 10 mEq [DSC]

Generic: 8 mEq, 10 mEq

Packet, Oral:

Klor-Con: 20 mEq (1 ea, 30 ea, 100 ea) [contains fd&c yellow #6 (sunset yellow); orange flavor]

Klor-Con: 20 mEq (1 ea [DSC], 30 ea [DSC], 100 ea [DSC]); 25 mEq (30 ea [DSC], 100 ea [DSC]) [sugar free; contains fd&c yellow #6 (sunset yellow); fruit flavor]

Generic: 20 mEq (1 ea, 30 ea, 100 ea)

Solution, Intravenous:

Potassium Chloride PROAMP: 2 mEq/mL (10 mL [DSC])

Generic: 20 mEq (1000 mL); 40 mEq (1000 mL); 0.4 mEq/mL (50 mL [DSC]); 10 mEq/100 mL (100 mL); 10 mEq/50 mL (50 mL); 20 mEq/100 mL (100 mL); 20 mEq/50 mL (50 mL); 40 mEq/100 mL (100 mL); 2 mEq/mL (5 mL, 10 mL, 20 mL, 30 mL, 250 mL); 20 mEq/L (1000 mL); 40 mEq/L (1000 mL [DSC]); Potassium 10 mEq/L, dextrose 5%, and sodium chloride 0.45% (1000 mL); Potassium 20 mEq/L and sodium chloride 0.45% (1000 mL); Potassium 20 mEq/L and sodium chloride 0.9% (1000 mL); Potassium 20 mEq/L, dextrose 5%, and sodium chloride 0.2% (500 mL, 1000 mL); Potassium 20 mEq/L, dextrose 5%, and sodium chloride 0.225% (500 mL, 1000 mL); Potassium 20 mEq/L, dextrose 5%, and sodium chloride 0.33% (500 mL [DSC], 1000 mL); Potassium 20 mEq/L, dextrose 5%, and sodium chloride 0.45% (500 mL, 1000 mL); Potassium 20 mEq/L, dextrose 5%, and sodium chloride 0.9% (1000 mL); Potassium 30 mEq/L, dextrose 5%, and sodium chloride 0.45% (1000 mL); Potassium 40 mEq/L and sodium chloride 0.9% (1000 mL); Potassium 40 mEq/L, dextrose 5%, and sodium chloride 0.45% (1000 mL); Potassium 40 mEq/L, dextrose 5%, and sodium chloride 0.9% (1000 mL)

Solution, Intravenous [preservative free]:

Generic: 10 mEq/100 mL (100 mL); 10 mEq/50 mL (50 mL); 20 mEq/50 mL (50 mL); 20 mEq/L (1000 mL)

Solution, Oral:

Generic: 20 mEq/15 mL (10%) (15 mL, 30 mL, 473 mL, 3800 mL); 40 MEQ/15ML (20%) (473 mL); 40 mEq/15 mL (20%) (473 mL)

Tablet Extended Release, Oral:

K-Tab: 8 mEq, 10 mEq [contains fd&c yellow #10 (quinoline yellow)]

K-Tab: 20 mEq

Klor-Con: 8 mEq [contains fd&c blue #1 aluminum lake, fd&c blue #2 aluminum lake]

Klor-Con 10: 10 mEq [contains fd&c yellow #10 aluminum lake, fd&c yellow #6 aluminum lake]

Klor-Con M10: 10 mEq

Klor-Con M15: 15 mEq

Klor-Con M15: 15 mEq [scored]

Klor-Con M20: 20 mEq

Klor-Con M20: 20 mEq [scored]

Generic: 8 mEq, 10 mEq, 20 mEq

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Capsule Extended Release, Oral:

Micro-K: 8 mEq

Solution, Intravenous:

Generic: 328 mg/100 mL ([DSC]); 20 mEq (1000 mL); 40 mEq (1000 mL); 0.2 mEq/mL (100 mL); 0.4 mEq/mL (50 mL, 100 mL); 10 mEq/100 mL (100 mL); 2 mEq/mL (10 mL, 20 mL, 100 mL); 20 mEq/L (1000 mL); 40 mEq/L (1000 mL); Potassium 10 mEq/L, dextrose 5%, and sodium chloride 0.45% (1000 mL); Potassium 20 mEq/L and sodium chloride 0.45% (1000 mL); Potassium 20 mEq/L and sodium chloride 0.9% (1000 mL); Potassium 20 mEq/L, dextrose 5%, and sodium chloride 0.2% (250 mL, 500 mL, 1000 mL); Potassium 20 mEq/L, dextrose 5%, and sodium chloride 0.225% (1000 mL); Potassium 20 mEq/L, dextrose 5%, and sodium chloride 0.33% (1000 mL); Potassium 20 mEq/L, dextrose 5%, and sodium chloride 0.45% (500 mL, 1000 mL); Potassium 20 mEq/L, dextrose 5%, and sodium chloride 0.9% (1000 mL); Potassium 30 mEq/L, dextrose 5%, and sodium chloride 0.45% (1000 mL); Potassium 40 mEq/L and sodium chloride 0.9% (1000 mL); Potassium 40 mEq/L, dextrose 5%, and sodium chloride 0.45% (1000 mL); Potassium 40 mEq/L, dextrose 5%, and sodium chloride 0.9% (1000 mL)

Tablet Extended Release, Oral:

Slo-Pot 600: 8 mEq

Generic: 8 mEq

Anatomic Therapeutic Chemical (ATC) Classification

• A12BA01
• B05XA01

Generic Available (US)

Yes

Pricing: US

Capsule, controlled release (Klor-Con Sprinkle Oral)

8 mEq (per each): $0.90

10 mEq (per each): $0.95

Capsule, controlled release (Potassium Chloride ER Oral)

8 mEq (per each): $0.89 - $0.94

10 mEq (per each): $0.94 - $5.29

Pack (Klor-Con Oral)

20 mEq (per each): $10.74

Pack (Potassium Chloride Oral)

20 mEq (per each): $10.67 - $10.74

Solution (KCl in Dextrose-NaCl Intravenous)

10 mEq/L 5-0.45%-% (per mL): $0.00 - $0.01

20 mEq/L 5-0.2%-% (per mL): $0.00 - $0.01

20 mEq/L 5-0.225%-% (per mL): $0.01

20 mEq/L 5-0.45%-% (per mL): $0.00 - $0.01

20 mEq/L 5-0.9%-% (per mL): $0.00 - $0.01

30 mEq/L 5-0.45%-% (per mL): $0.00 - $0.01

40 mEq/L 5-0.45%-% (per mL): $0.00 - $0.01

40 mEq/L 5-0.9%-% (per mL): $0.00 - $0.01

Solution (Potassium Chloride in Dextrose Intravenous)

20 mEq/L 5% (per mL): $0.00 - $0.01

40 mEq/L 5% (per mL): $0.00

Solution (Potassium Chloride in NaCl Intravenous)

20 mEq/L 0.45% (per mL): $0.00 - $0.01

20 mEq/L 0.9% (per mL): $0.00 - $0.01

40 mEq/L 0.9% (per mL): $0.00 - $0.01

Solution (Potassium Chloride Intravenous)

2 mEq/mL (per mL): $0.21 - $1.08

10 mEq/100 mL (per mL): $0.04 - $0.06

10 mEq/50 mL (per mL): $0.08 - $0.12

20 mEq/100 mL (per mL): $0.04 - $0.06

20 mEq/50 mL (per mL): $0.08 - $0.12

40 mEq/100 mL (per mL): $0.04

Solution (Potassium Chloride Oral)

20 MEQ/15ML (10%) (per mL): $0.96 - $1.52

40 MEQ/15ML (20%) (per mL): $1.62

Tablet, controlled release (K-Tab Oral)

8 mEq (per each): $0.66

10 mEq (per each): $1.01

20 mEq (per each): $0.99

Tablet, controlled release (Klor-Con 10 Oral)

10 mEq (per each): $0.56

Tablet, controlled release (Klor-Con M10 Oral)

10 mEq (per each): $0.60

Tablet, controlled release (Klor-Con M15 Oral)

15 mEq (per each): $0.99

Tablet, controlled release (Klor-Con M20 Oral)

20 mEq (per each): $0.63

Tablet, controlled release (Klor-Con Oral)

8 mEq (per each): $0.54

Tablet, controlled release (Potassium Chloride Crys ER Oral)

10 mEq (per each): $0.60 - $0.86

20 mEq (per each): $0.63 - $0.93

Tablet, controlled release (Potassium Chloride ER Oral)

8 mEq (per each): $0.47 - $0.54

10 mEq (per each): $0.39 - $0.60

20 mEq (per each): $0.63

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Mechanism of Action

Potassium is the major cation of intracellular fluid and is essential for the conduction of nerve impulses in heart, brain, and skeletal muscle; contraction of cardiac, skeletal and smooth muscles; maintenance of normal renal function, acid-base balance, carbohydrate metabolism, and gastric secretion

Pharmacodynamics/Kinetics

Absorption: Well absorbed from upper GI tract

Distribution: Enters cells via active transport from extracellular fluid

Excretion: Primarily urine; skin and feces (small amounts); most intestinal potassium reabsorbed

Local Anesthetic/Vasoconstrictor Precautions

No information available to require special precautions

Effects on Dental Treatment

No significant effects or complications reported

Effects on Bleeding

No information available to require special precautions

Related Information

• Management of Drug Extravasations
• Oral Medications That Should Not Be Crushed or Altered

Index Terms

KCl; Kdur

FDA Approval Date

June 30, 1971

References

Adeli K, Higgins V, Nieuwesteeg M, et al. Biochemical marker reference values across pediatric, adult, and geriatric ages: establishment of robust pediatric and adult reference intervals on the basis of the Canadian Health Measures Survey. Clin Chem. 2015;61(8):1049-1062.[PubMed 26044506]

Alfonzo AV, Isles C, Geddes C, et al, “Potassium Disorders - Clinical Spectrum and Emergency Management,” Resuscitation, 2006, 70(1):10-25.[PubMed 16600469]

ASPEN Board of Directors and the Clinical Guidelines Task Force, “Guidelines for the Use of Parenteral and Enteral Nutrition in Adult and Pediatric Patients,” JPEN J Parenter Enteral Nutr, 2002, 26(1 Suppl):22-4.[PubMed 11841046]

ASPEN Board of Directors and the Clinical Guidelines Task Force, “Guidelines for the Use of Parenteral and Enteral Nutrition in Adult and Pediatric Patients,” JPEN J Parenter Enteral Nutr, 2002, 26(1 Suppl):25-32.[PubMed 11841046]

Bonilla-Félix M. Potassium regulation in the neonate. Pediatr Nephrol. 2017;32(11):2037-2049.[PubMed 28378030]

Brophy DF. Chapter 36. Disorders of Potassium and Magnesium Homeostasis. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey L. eds. Pharmacotherapy: A Pathophysiologic Approach, 9e. New York, NY: McGraw-Hill; 2014.

Corkins MR, Balint J, Bobo E, et al, eds. The A.S.P.E.N Pediatric Nutrition Support Core Curriculum. 2nd ed. Silver Spring: MD: American Society of Parenteral and Enteral Nutrition, 2015.

Flurie RW, Brophy DF, et al. Pharmacotherapy: A Pathophysiologic Approach, 10th ed. Chapter 51: Disorders of Potassium and Magnesium Homeostasis. New York, NY: McGraw-Hill Education. Available at http://accesspharmacy.mhmedical.com/content.aspx?bookid=1861&sectionid=134127639. 2017.

Fuhrman B, Zimmerman J, eds. Pediatric Critical Care. 5th ed. Elsevier Health; 2017.

Greeley C, Snell J, Colaco A, et al. Pediatric reference ranges for electrolytes and creatinine. Clin Chem. 1993;39(6):1172.

Hadaway L. Infiltration and extravasation [published correction appears in Am J Nurs. 2007;107(10):15]. Am J Nurs. 2007;107(8):64-72.[PubMed 17667395]

Hamill RJ, Robinson LM, Wexler HR, Moote C. Efficacy and safety of potassium infusion therapy in hypokalemic critically ill patients. Crit Care Med. 1991;19(5):694-699.[PubMed 2026032]

Hurst S, McMillan M. Innovative solutions in critical care units: extravasation guidelines. Dimens Crit Care Nurs. 2004;23(3):125-128.[PubMed 15192356]

IOM (Institute of Medicine), Dietary Reference Intakes for Water, Potassium, Sodium, Chloride, and Sulfate, Washington, DC: National Academy Press, 2004.

Khilnani P, “Electrolyte Abnormalities in Critically Ill Children,” Crit Care Med, 1992, 20(2):241-50.[PubMed 1737458]

Klaus JR, Knodel LC, Kavanagh RE. Administration guidelines for parenteral drug therapy. Part I: Pediatric patients. J Pharm Technol. 1989;5(3):101-128.[PubMed 10318297]

Kliegman RM, Stanton BF, St. Gemell JW, et al, eds. Nelson Textbook of Pediatrics. 20th ed. Philadelphia, PA: Saunders Elsevier; 2016.

Klor-con (potassium chloride) [prescribing information]. Maple Grove, MN: Upsher-Smith Laboratories, LLC; August 2019.

Klor-con M (potassium chloride) [prescribing information]. Maple Grove, MN: Upsher-Smith Laboratories, LLC; March 2019.

Klor-Con M tablet (potassium chloride) [prescribing information]. Princeton, NJ: Sandoz Inc; April 2014.

Klor-Con Powder (potassium chloride) [prescribing information]. Maple Grove, MN: Upsher-Smith Laboratories, LLC; August 2019.

Klor-Con Sprinkle (potassium chloride) [prescribing information]. Maple Grove, MN: Upsher-Smith Labs; September 2017.

Knudson JD, Lowry AW, Price JF, Moffett BS. Response to intravenous potassium chloride supplementation in pediatric cardiac intensive care patients. Pediatr Cardiol. 2013;34(4):887-892.[PubMed 23124387]

Kraft MD, Btaiche IF, Sacks GS, Kudsk KA. Treatment of electrolyte disorders in adult patients in the intensive care unit. Am J Health Syst Pharm. 2005, 62(16):1663-1682.[PubMed 16085929]

Kruse JA, Carlson RW. Rapid correction of hypokalemia using concentrated intravenous potassium chloride infusions. Arch Intern Med. 1990;150(3):613-617.[PubMed 2310280]

K-Tab (potassium chloride) [prescribing information]. North Chicago, IL: AbbVie Inc; April 2018.

Joint Commission on Accreditation of Healthcare Organizations, “2005 National Patient Safety Goals,” available at http://www.jointcommission.org/

Lafreniere JA, Hamilton DP, Carr RR. Assessing the guidelines for potassium replacement in pediatric oncology patients receiving amphotericin B. J Pediatr Pharmacol Ther. 2006;11(4):223-232.[PubMed 23115538 ]

MacCara ME. Extravasation: a hazard of intravenous therapy. Drug Intell Clin Pharm. 1983;17(10):713.[PubMed 6628223]

Mirtallo J, Canada T, Johnson D, et al. Safe practices for parenteral nutrition. JPEN J Parenter Enteral Nutr. 2004;28(6):S39-S70.[PubMed 15568296]

Moffett BS, McDade E, Rossano JW, Dickerson HA, Nelson DP. Enteral potassium supplementation in a pediatric cardiac intensive care unit: evaluation of a practice change. Pediatr Crit Care Med. 2011;12(5):552-554.[PubMed 21297518 ]

Murray KL, Wright D, Laxton B, Miller KM, Meyers J, Englebright J. Implementation of standardized pediatric i.v. medication concentrations. Am J Health Syst Pharm. 2014;71(17):1500-1508

Potassium Chloride (flexible plastic container) [package insert]. Deerfield, IL: Baxter Healthcare Corporation; June 2019.

Potassium chloride for injection [prescribing information]. Deerfield, IL: Baxter Healthcare Corporation; June 2019.

Potassium chloride injection [product monograph]. Mississauga, Ontario, Canada: Baxter Corporation; January 2019.

Potassium chloride oral solution [prescribing information]. Weston, FL: Apotex Corp; February 2018.

Reynolds PM, MacLaren R, Mueller SW, Fish DN, Kiser TH. Management of extravasation injuries: a focused evaluation of noncytotoxic medications. Pharmacotherapy. 2014;34(6):617-632.[PubMed 24420913]

Schaber DE, Uden DL, Stone FM, Singh A, Katkov H, Bessinger FB. Intravenous KCl supplementation in pediatric cardiac surgical patients. Pediatr Cardiol. 1985;6(1):25-28.[PubMed 4011464 ]

Weiss-Guillet EM, Takala J, and Jakob SM, “Diagnosis and Management of Electrolyte Emergencies,” Best Pract Res Clin Endocrinol Metab, 2003, 17(4):623-51.[PubMed 14687593]

Zenk KE. Management of intravenous extravasations. Infusion. 1981;5(4):77-79.

Brand Names: International

Addi-K (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TH, TN, TZ, UG, ZM); Alkay ER (LK); Apo-K (HK, JO, MY, SG); Beacon K (MY); Budaxiu (CN); Chloropotassuril (BE); Clor-K-Zat (MX); Clotassio (BR); Co-Salt (AR); Control K (AR); Corpotasin (MX); Crysta K (BD); Di Jia (CN); Diffu-K (FR); Duro-K (AU); Dyna-K (PH); Electro K (BD); Enpott (TH); Flexivial (ZA); Geo (EG); Gluco-K (AR); Ionclor (BR); K-Card (IN); K-Chlor (PH); K-Contin (BF, BJ, CI, ET, GH, GM, GN, KE, KR, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM); K-Contin Continus (AE); K-Dur (MX); K-Norm (PH); K-Retard (UY); K-Supply (JP); K-Tab (PK); Kadalex (IT); Kaion Retard (CL); Kaldyum (HU, PL); Kaleorid (DK, FI, FR, IS, NO, SE); Kali-Sterop (BE); Kaligen (PH); Kalinor-Retard P (DE); Kalinorm (FI); Kaliolite (MX); Kalipoz (PL, UA); Kalitabs (DK); Kalium (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, PH, SC, SD, SL, SN, TN, TZ, UG, ZM); Kalium-R (HN, HU); Kalnormin (CZ); Kalytes (PH); Katelin (PL); Kation (UY); Kay-Cee-L (GB, IE, MT); Kay-Ciel (IN); Kaylyte (TH); KCL Retard (BH, HN, IQ, IR, IT, LB, LY, OM, SA, SY, YE); Kelefusin (MX); Keylyte (IN); KSR (HK, ID); Lejia (CN); Lento-Kalium (IT); Micro-Kalium Retard (AT); Orakit (AR); Perennum (PY); Plenisk-K (ZA); Plus Kalium Retard (CH); Pota-K (EG); Potasion (ES); Potassin (JO); Potassride (TH); Potazek (PL); Potklor (IN); Potrelease TR (MY); Rekawan (DE); Sando-K (GB); Sandoz K (ZA); Slow-K (AR, AT, AU, BB, BF, BH, BJ, BM, BR, BS, BZ, CI, CL, EG, ET, GB, GH, GM, GN, GY, IE, IL, IQ, IR, JM, KE, KW, LB, LR, LY, MA, ML, MR, MT, MU, MW, MY, NE, NG, NL, OM, PR, SA, SC, SD, SG, SL, SN, SR, SY, TN, TT, TW, TZ, UG, UY, YE, ZA, ZM, ZW); Slow-K MR (CY, TR); Span-K (AU, HK, MY, NZ, PH, SG); Susta-K (ZW); Sylvite (PH); Tascit (LK); Xian Jia (CN); Xin Jian Ju (CN); Zerosodio (BR)

Last Updated 2/27/20